Researchers advance COVID-19 antibody knowledge with paper in journal

October 01, 2020

Memphis, Tenn. (September 30, 2020) - Researchers at the University of Tennessee Health Science Center working with colleagues at MD Anderson Cancer Center in Houston have found that some antibodies to SARS-CoV-2, the virus that causes COVID-19, are more protective than others, when it comes to reinfection.

This information, discovered from the joint study and published online in the Journal of Clinical Investigation's JCI Insight, has implications for the overall understanding of the virus and whether infection actually does trigger immunity, according to Michael Whitt, PhD, associate dean of the Office of Medical Education in the UTHSC College of Medicine, chair of the Department of Medical Education, and a professor and former chair of the Department of Microbiology, Immunology, and Biochemistry. Dr. Whitt is one of the principal investigators on the antibody study, which is ongoing at UTHSC.

Dr. Whitt and his laboratory team, which includes three fourth-year medical students and two Master of Medical Laboratory Science students, used an assay or test procedure developed in his lab roughly 25 years ago to study the infection mechanism of Ebolavirus. They applied that assay to study infection of and immunity generated against SARS-CoV-2. Dr. Whitt was contacted by researchers at MD Anderson to use his assay to test for the presence of neutralizing antibodies in samples from 134 hospitalized COVID patients and 464 healthy individuals obtained between June 2017 and June 2020.

"We ended up running samples for them (MD Anderson), and those data are presented in the paper," Dr. Whitt said. "Companies have developed assays to show whether people have SARS-CoV-2 antibodies, but these assays only provide a yes or no answer. So why is our work important? We can determine the amount of neutralizing antibody present in the blood, and neutralizing antibodies are the ones that can prevent the individual from becoming infected. If you have an antibody to an internal component of the virus, then that means you have been infected, but those antibodies won't prevent infection.

"Neutralizing antibodies are directed to the spike (S) protein, which is responsible for the binding of the virus to receptors on a host cell and for entry of the virus into the cell," Dr. Whitt explained. "However, not all antibodies to the S protein have neutralizing activity, so it is only a subset of antibodies to the S protein that can prevent infection. One of the questions we wanted to address is, do all people who have had the disease, COVID-19, generate neutralizing antibodies? That answer is clearly, no. The other question is, for those who do produce neutralizing antibodies, how much do they make?"

Further research will help answer questions about immunity. This is vital to plans for reopening the community.

"What we don't know is how much neutralizing antibody is needed to prevent infection or reinfection," Dr. Whitt said. "Just because you have detectable antibodies doesn't mean that you're protected from infection."

As a medical educator, Dr. Whitt said he is proud that the research in his lab has included students. "I think that speaks to the academic and training opportunities here at UTHSC," he said.
-end-
Along with Dr. Whitt, researchers in the Department of Microbiology, Immunology, and Biochemistry at UTHSC are working on ways to test the general population in Memphis for the SARS-CoV-2 antibody. Professor Maria Gomes-Solecki, DVM, and her team have developed and are vetting a prototype ELISA (enzyme-linked immunosorbent assay), a blood test that could be used to mass-test antibodies in the community that would signal individual exposure.

Colleen Jonsson, PhD, professor and the Van Vleet Chair of Excellence in Virology and director of the Regional Biocontainment Laboratory at UTHSC, is leading the efforts with live SARS-CoV-2 to identify neutralizing antibodies and therapeutics to treat COVID-19. Dr. Jonsson is the lead investigator on a protocol to perform testing of the general population in Memphis for the SARS-CoV-2 antibodies.

As Tennessee's only public, statewide, academic health system, the mission of the University of Tennessee Health Science Center is to bring the benefits of the health sciences to the achievement and maintenance of human health through education, research, clinical care, and public service, with a focus on the citizens of Tennessee and the region. The main campus in Memphis includes six colleges: Dentistry, Graduate Health Sciences, Health Professions, Medicine, Nursing and Pharmacy. UTHSC also educates and trains medicine, pharmacy, and/or health professions students, as well as medical residents and fellows, at major sites in Knoxville, Chattanooga and Nashville. For more information, visit http://www.uthsc.edu. Find us on Facebook: facebook.com/uthsc, on Twitter: twitter.com/uthsc and on Instagram: instagram.com/uthsc.


University of Tennessee Health Science Center

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.